First patient undergoes Luxturna gene therapy on NHS
Jake Ternet, patient at Moorfields Eye Hospital was the first in the UK to receive the treatment.
Read Moreby Anna Smith | Feb 18, 2020 | News | 0
Jake Ternet, patient at Moorfields Eye Hospital was the first in the UK to receive the treatment.
Read Moreby Anna Smith | Sep 4, 2019 | News | 0
The treatment has been approved for RPE65-mediated inherited retinal dystrophies.
Read Moreby Selina McKee | Nov 25, 2018 | News | 0
Novartis’ Luxturna has been approved by regulators in Europe to treat a rare inherited condition that causes sight loss.
Read Moreby Selina McKee | Sep 24, 2018 | News | 0
Marking a bumper month for Committee for Medicinal Products for Human Use (CHMP) decisions, 13 medicines have been put forward for approval in the region, including three orphan medicines.
Read Moreby Selina McKee | Jan 25, 2018 | News | 0
Novartis has bought itself rights to Spark Therapeutic’s gene therapy for a certain type of vision loss, in a deal worth up to $170 million.
Read Moreby Selina McKee | Dec 20, 2017 | News | 0
Spark Therapeutics’ Luxturna has become the first gene therapy ever to be approved by the US Food and Drug Administration for an inherited condition.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
